Full Text View
Tabular View
No Study Results Posted
Related Studies
Long Term Safety and Tolerability Study in Approximately 350 Subjects With Moderate to Severe Chronic, Non-Malignant Pain
This study has been completed.
First Received: September 13, 2005   Last Updated: October 24, 2007   History of Changes
Sponsored by: Abbott
Information provided by: Abbott
ClinicalTrials.gov Identifier: NCT00195728
  Purpose

The purpose of the study is to evaluate the safety of Vicodin CR (combination opioid and acetaminophen containing product) in patients with chronic pain due to osteoarthritis or low back pain.


Condition Intervention Phase
Moderate to Severe Chronic, Non-Malignant Pain
Drug: Hydrocodone/Acetaminophen
Phase III

Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study
Official Title: An Open-Label Study Evaluating the Safety and Tolerability of Long Term Administration of Hydrocodone/Acetaminophen Extended ReleaseTablets (Vicodin® CR) in Subjects With Moderate to Severe Chronic, Non-Malignant Pain

Resource links provided by NLM:


Further study details as provided by Abbott:

Primary Outcome Measures:
  • Safety evaluation

Secondary Outcome Measures:
  • Quality of Life

Estimated Enrollment: 350
Study Start Date: July 2005
  Eligibility

Ages Eligible for Study:   21 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Males and Females between 21 and 75 years of age

    • Females must be of non-child bearing potential or practicing birth control
  • Moderate to severe mechanical low back pain OR moderate to severe OA of the hip or knee pain
  • Require medicine for pain the majority of days in the previous 3 months, AND for at least 4 days per week, during the previous 4 weeks.
  • Pain is not controlled with non-opioid analgesics or is contraindicated due to side effects and/or currently receiving opioid therapy equivalent to 40 mg/day of morphine or less

Exclusion Criteria:

  • Pregnant and/or breastfeeding females or females planning to become pregnant during the course of the study
  • Incapacitated, bedridden, or confined to a wheelchair permitting little or no self-care
  • Injury to the index joint or lower back within 3 months of study
  • History of any of the following:

    • Major surgery to the lower back within the last 5 years OR
    • Joint replacement/reconstruction to the index joint OR
    • Arthroscopic or open surgery to the index joint within the last year OR
    • Any surgery within 3 months of study
  • Osteoporotic compression fracture, traumatic vertebral fracture or invasive intervention for low back pain within the last year.
  • Abnormal neurological exam, or lower extremity symptoms characteristic of neurogenic pain
  • History of inflammatory or infectious arthritis, tumors or infections of spinal cord, spinal stenosis, fibromyalgia or other chronic painful condition
  • Severe gastrointestinal narrowing
  • History of peritonitis, cystic fibrosis, chronic intestinal eudoobstruction, or Meckel's diverticulum.
  • Has received

    • Oral, intramuscular (IM), intravenous (IV) or non-index joint intra- articular corticosteroids within 1 month of study OR
    • Intra-articular corticosteroids at the index joint or epidural corticosteroids to the lower back region within 2 months of study, OR
    • Viscosupplementation therapy to index joint within 4 months of study
  • History of drug (licit or illicit) or alcohol abuse/addiction
  • Positive result for drugs of abuse at screening.
  • Chronic heavy drinker, consuming more than 4 alcoholic drinks per day.
  • History of malnutrition or starvation or is likely to fast for more than 4 consecutive days during the course of the study.
  • Medical condition or illness other than OA/CLBP, which is not well controlled
  • History of allergic reaction or a clinically significant sensitivity or intolerance to opioids and/or acetaminophen.
  • Newly diagnosed medical condition
  • Clinically significant infection/injury/illness within 1 month of study
  • Receiving systemic chemotherapy, or has an active malignancy of any type, or has been diagnosed with cancer within the past 5 years. Basal cell carcinoma of the skin that has been successfully treated will be permitted.
  • Known or suspected history of Human Immunodeficiency Virus.
  • Positive Hepatitis Screen
  • Clinically significant abnormalities in clinical chemistry, hematology or urinalysis
  • Received any investigational drug within 1 month of study
  • History of major psychiatric disorder
  • Active or uncontrolled seizure disorder.
  • Requires treatment with monoamine oxidase inhibitors (MAOIs), or tricyclic antidepressants during the course of the study.
  • Surgical procedure planned, or scheduled during the course of this study.
  • Ongoing workman's compensation claim or litigation.
  • Previous participation in the M03-666 study.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00195728

Locations
United States, Illinois
Global Medical Information - Abbott
North Chicago, Illinois, United States, 60064
Sponsors and Collaborators
Abbott
Investigators
Study Director: Global Medical Information Abbott
  More Information

No publications provided

Study ID Numbers: M03-666
Study First Received: September 13, 2005
Last Updated: October 24, 2007
ClinicalTrials.gov Identifier: NCT00195728     History of Changes
Health Authority: United States: Food and Drug Administration

Keywords provided by Abbott:
Hydrocodone/Acetaminophen
Vicodin CR

Study placed in the following topic categories:
Oxycodone
Central Nervous System Depressants
Pain
Narcotics
Naphazoline
Analgesics, Non-Narcotic
Guaifenesin
Hydrocodone
Analgesics
Peripheral Nervous System Agents
Phenylpropanolamine
Acetaminophen
Analgesics, Opioid

Additional relevant MeSH terms:
Respiratory System Agents
Oxycodone
Physiological Effects of Drugs
Central Nervous System Depressants
Narcotics
Pharmacologic Actions
Analgesics, Non-Narcotic
Sensory System Agents
Therapeutic Uses
Hydrocodone
Analgesics
Peripheral Nervous System Agents
Antitussive Agents
Central Nervous System Agents
Acetaminophen
Analgesics, Opioid

ClinicalTrials.gov processed this record on August 30, 2009